GSK, with new CEO Luke Miels at the helm, unveils its growth strategy emphasizing new drug development, strategic acquisitions, and a focus on specialty medicines. The company aims for over £40 billion in sales by 2031, with shares rising on the announcement. While vaccine sales face uncertainty, specialty medicines are expected to drive growth.
GSK , under the leadership of its new CEO Luke Miels , is embarking on its next phase of growth with a strategic focus on accelerating sales growth and expediting the development of new medicines. Miels, who took the helm in January, outlined the company's future direction, emphasizing a commitment to programs that can revolutionize the standard of care and strategic bolt-on acquisitions.
This approach aims to capitalize on the research ramp-up and navigate the upcoming patent expirations for its prominent HIV drugs. Miels expressed confidence in the company's ability to achieve its goals, stating, We need to accelerate what we have and to add to it via smart business development. The market responded positively to Miels's first outlook presentation, with GSK shares experiencing a notable surge, reaching their highest level in nearly 25 years. This recovery contrasts with the performance of some European competitors, particularly in the face of tariff threats and drug pricing pressures from the US government. The positive momentum stems from Miels's appointment, strong earnings performance, and the growth of its specialty medicines business. The company is set to reach the sales target of generating more than £40 billion (US$55 billion) by 2031.\GSK's strategic plan involves no fundamental alteration to its capital allocation strategy. Miels indicated that the company would primarily target deals in the £2 billion to £4 billion range, with certain exceptions. The company's acquisition strategy will focus on identifying valuable assets that are readily available to enhance its late-stage pipeline. The focus lies on programs with reasonably established scientific foundations. This strategy is highlighted by the recent US$2.2 billion acquisition of RAPT Therapeutics, with their experimental food allergy drug. The company's revenue forecast for the current year is anticipated to grow between 3% and 5% at constant currency rates, following a 7% increase in the previous year, which exceeded expectations. The forecast is, however, slightly below the consensus, mainly due to foreign exchange pressures, according to Barclays analysts. GSK's core earnings per share for the three months ended Dec 31 stood at 25.5 pence, after sales increased by 8% to £8.62 billion, surpassing expectations. To sustain growth, new product launches are essential for GSK. The company secured five US regulatory approvals last year, including for asthma drug Exdensur and blood cancer drug Blenrep, which are expected to generate significant peak sales. The future performance of the company is heavily reliant on these drugs, and GSK is aiming to increase their global reach.\Looking ahead, GSK anticipates that its 2026 sales from its vaccines business and general medicines unit will experience a low-single-digit percentage decline or remain stable. This forecast reflects the current uncertainty of the vaccines business, particularly in the US. However, the company's specialty medicines business is predicted to exhibit low-double-digit growth. This balanced outlook emphasizes GSK's strategic shift toward specialty medicines, aiming to mitigate potential revenue challenges in other areas. The company's success relies on the effective execution of its strategic vision under Miels's leadership, which includes bolstering its pipeline and focusing on areas of innovation. The strategic focus will be placed on existing medicines to maximize revenue and the integration of new medicines will contribute to revenue growth. The company will be looking for key growth drivers that will lead to success over the next five years. This next phase will involve careful planning and development of key products that will lead to long-term success
GSK Luke Miels Pharmaceuticals Acquisitions Specialty Medicines
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Palantir CEO Defends Surveillance Tech Amidst Sales JumpPalantir Technologies CEO Alex Karp defends the company's surveillance technology, citing safeguards against government overreach, while reporting a significant increase in sales, driven partly by government contracts, despite growing scrutiny of companies working with U.S. Immigration and Customs Enforcement (ICE).
Read more »
Organization Names Dr. Mazatul 'Aini Shahar as New Group CEOThe organization has appointed Dr. Mazatul 'Aini Shahar Abdul Malek Shahar as its group chief executive officer, effective February 4, 2026. This announcement marks a significant leadership change, highlighting Dr. Mazatul's extensive experience in transformation, finance, and strategic fundraising. The board executive committee will provide ongoing support during the transition.
Read more »
Ringgit snaps two‑day losing streak on optimism over Malaysia’s economic growth outlookKUALA LUMPUR, Feb 3 — The ringgit rebounded on Tuesday, snapping a two-day losing streak as it strengthened against the US dollar, other major currencies and Asean peers, buoyed...
Read more »
Ringgit ends higher against dollar, regional currencies on continued optimism over Malaysia’s economic growth outlookKUALA LUMPUR, Feb 3 — The ringgit closed higher against the US dollar, other major currencies and Asean peers on Tuesday on continued optimism over Malaysia’s economic growth...
Read more »
Ringgit snaps two-day losing streak on optimism over economic growthThe purchasing managers’ index (PMI) rose to a 20-month high in January 2026, marking the third consecutive month of manufacturing sector growth, analysts say.
Read more »
TomTom sees lower to steady revenue in 2026, followed by growth in 2027For Chinese New Year 2026, hair trends lean into expressive individuality balanced with polish. Cuts are modern yet wearable, favouring movement, texture and shape over rigidity.
Read more »